These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33314293)

  • 41. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease.
    Prasuhn J; Prasuhn M; Fellbrich A; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Münte TF; Hanssen H; Heldmann M; Brüggemann N
    Neurology; 2021 Sep; 97(10):e1007-e1016. PubMed ID: 34187859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies.
    Kitao S; Matsusue E; Fujii S; Miyoshi F; Kaminou T; Kato S; Ito H; Ogawa T
    Neuroradiology; 2013 Aug; 55(8):947-953. PubMed ID: 23673875
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis.
    Xing Y; Sapuan AH; Martín-Bastida A; Naidu S; Tench C; Evans J; Sare G; Schwarz ST; Al-Bachari S; Parkes LM; Kanavou S; Raw J; Silverdale M; Bajaj N; Pavese N; Burn D; Piccini P; Grosset DG; Auer DP
    Mov Disord; 2022 May; 37(5):1028-1039. PubMed ID: 35165920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved black-blood imaging using DANTE-SPACE for simultaneous carotid and intracranial vessel wall evaluation.
    Xie Y; Yang Q; Xie G; Pang J; Fan Z; Li D
    Magn Reson Med; 2016 Jun; 75(6):2286-94. PubMed ID: 26152900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subtypes evaluation of motor dysfunction in Parkinson's disease using neuromelanin-sensitive magnetic resonance imaging.
    Xiang Y; Gong T; Wu J; Li J; Chen Y; Wang Y; Li S; Cong L; Lin Y; Han Y; Yin L; Wang G; Du Y
    Neurosci Lett; 2017 Jan; 638():145-150. PubMed ID: 27993708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Convolutional neural network-based segmentation can help in assessing the substantia nigra in neuromelanin MRI.
    Le Berre A; Kamagata K; Otsuka Y; Andica C; Hatano T; Saccenti L; Ogawa T; Takeshige-Amano H; Wada A; Suzuki M; Hagiwara A; Irie R; Hori M; Oyama G; Shimo Y; Umemura A; Hattori N; Aoki S
    Neuroradiology; 2019 Dec; 61(12):1387-1395. PubMed ID: 31401723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network.
    Gaurav R; Valabrègue R; Yahia-Chérif L; Mangone G; Narayanan S; Arnulf I; Vidailhet M; Corvol JC; Lehéricy S
    Neuroimage Clin; 2022; 36():103250. PubMed ID: 36451356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deep Learning-Based Neuromelanin MRI Changes of Isolated REM Sleep Behavior Disorder.
    Gaurav R; Pyatigorskaya N; Biondetti E; Valabrègue R; Yahia-Cherif L; Mangone G; Leu-Semenescu S; Corvol JC; Vidailhet M; Arnulf I; Lehéricy S
    Mov Disord; 2022 May; 37(5):1064-1069. PubMed ID: 35102604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Usefulness of the Delay Alternating with Nutation for Tailored Excitation Pulse with T1-Weighted Sampling Perfection with Application-Optimized Contrasts Using Different Flip Angle Evolution in the Detection of Cerebral Metastases: Comparison with MPRAGE Imaging.
    Kim D; Heo YJ; Jeong HW; Baek JW; Han JY; Lee JY; Jin SC; Baek HJ
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1469-1475. PubMed ID: 31371358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI.
    Shinde S; Prasad S; Saboo Y; Kaushick R; Saini J; Pal PK; Ingalhalikar M
    Neuroimage Clin; 2019; 22():101748. PubMed ID: 30870733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI.
    Langley J; Huddleston DE; Liu CJ; Hu X
    MAGMA; 2017 Apr; 30(2):121-125. PubMed ID: 27687624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of contrast-enhanced T1-weighted imaging using DANTE-SPACE, PETRA, and MPRAGE: a clinical evaluation of brain tumors at 3 Tesla.
    Fu Q; Cheng QG; Kong XC; Liu DX; Guo YH; Grinstead J; Zhang XY; Lei ZQ; Zheng CS
    Quant Imaging Med Surg; 2022 Jan; 12(1):592-607. PubMed ID: 34993104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Image-Quality Assessment of 3D Intracranial Vessel Wall MRI Using DANTE or DANTE-CAIPI for Blood Suppression and Imaging Acceleration.
    Sannananja B; Zhu C; Colip CG; Somasundaram A; Ibrahim M; Khrisat T; Mossa-Basha M
    AJNR Am J Neuroradiol; 2022 Jun; 43(6):837-843. PubMed ID: 35618420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuromelanin-sensitive MRI of the substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson's disease.
    Wang J; Huang Z; Li Y; Ye F; Wang C; Zhang Y; Cheng X; Fei G; Liu K; Zeng M; Zhong C; Jin L
    Parkinsonism Relat Disord; 2019 Jan; 58():3-8. PubMed ID: 30037690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach.
    Chen X; Huddleston DE; Langley J; Ahn S; Barnum CJ; Factor SA; Levey AI; Hu X
    Magn Reson Imaging; 2014 Dec; 32(10):1301-6. PubMed ID: 25086330
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.
    Castellanos G; Fernández-Seara MA; Lorenzo-Betancor O; Ortega-Cubero S; Puigvert M; Uranga J; Vidorreta M; Irigoyen J; Lorenzo E; Muñoz-Barrutia A; Ortiz-de-Solorzano C; Pastor P; Pastor MA
    Mov Disord; 2015 Jun; 30(7):945-52. PubMed ID: 25772492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy.
    Simões RM; Castro Caldas A; Grilo J; Correia D; Guerreiro C; Pita Lobo P; Valadas A; Fabbri M; Correia Guedes L; Coelho M; Rosa MM; Ferreira JJ; Reimão S
    BMC Neurol; 2020 Nov; 20(1):432. PubMed ID: 33243166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Substantia nigra neuromelanin magnetic resonance imaging in patients with different subtypes of Parkinson disease.
    Wang L; Yan Y; Zhang L; Liu Y; Luo R; Chang Y
    J Neural Transm (Vienna); 2021 Feb; 128(2):171-179. PubMed ID: 33559725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.